Business News • PR NewsWire • CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation

CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation

CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation

TARRYTOWN, N.Y. and PARIS, Jan. 31, 2022 /PRNewswire/ -- Recommendation based on pivotal trial that showed Dupixent significantly reduced severe asthma attacks and improved lung function in children aged 6 to 11 years Dupixent is the only biologic to show improved lung function in a...

View More : https://www.prnewswire.com:443/news-releases/chmp-recommends-approval-of-dupixent-dupilumab-for-children-aged-6-to-11-ye...

Releted News by prnewswire

Organic Soap Market - 35% of Growth to Originate from North America|Rising adoption of organic BPC products to Boost Market |17000+ Technavio Reports

Digital Signature Market - 33% of Growth to Originate from North America | Rising number of partnerships and acquisitions to Boost Market | 17000+ Technavio Reports

InsureTech Market to register a growth of USD 33.73 billion at a CAGR of 45.28% | Improvement in business efficiency is a key driver | Technavio

ROSEN, A TOP RANKED LAW FIRM, Encourages Shattuck Labs, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action Commenced by the Firm - STTK